Mumbai, August 11: Zydus Lifesciences announced its financial results for the first quarter of the current fiscal year on Tuesday. The company reported a significant annual decline of 36% in its consolidated net profit.
In an exchange filing, Zydus revealed that its net profit for the June quarter fell to ₹940 crores, down 35.9% from ₹1,467 crores during the same period last year.
Despite the profit drop, the pharmaceutical giant saw a 22% increase in operational revenue, reaching ₹8,017 crores compared to ₹6,574 crores a year earlier.
However, profit margins faced pressure, with EBITDA decreasing by 7.6% to ₹1,930 crores, down from ₹2,089 crores in the previous year.
Consequently, the EBITDA margin fell from 31.8% in the same quarter last year to 24.1%.
Despite the weak earnings report, investors appeared largely unaffected. Following the announcement, Zydus Lifesciences shares traded at ₹1,126, reflecting a 0.63% increase or ₹7 from the previous close.
The stock performance has been mixed over various timeframes. In the last five trading sessions, shares rose by 1.41% or ₹15.70. However, over the past month, the stock has decreased by 0.52% or ₹5.90. In the last six months, Zydus shares have surged by 25.43%, with an increase of ₹228.40 in value.
Since the start of the year, the stock has gained 23.20% or ₹212.25.
Zydus Lifesciences, formerly known as Cadila Healthcare, is one of India’s leading pharmaceutical companies. Established in 1952 and headquartered in Ahmedabad, the company rebranded itself as Zydus Lifesciences in 2022.
Under the leadership of Chairman Pankaj R. Patel, Zydus operates in over 50 countries and has more than 30 manufacturing facilities worldwide. The company’s diverse portfolio includes generic medicines, active pharmaceutical ingredients (APIs), vaccines, biosimilars, and specialty products.
Through its subsidiary Zydus Wellness, the company also offers several consumer brands, including Glucon-D, Sugar Free, Complan, Nicacin, and Everyuth.
Leave a Comment